8-K Announcements
6Material company update
Apr 10, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Feb 26, 2026·SEC
Intellia Therapeutics, Inc.(NTLA)Earnings, Financials & Key Ratios
NTLA•NASDAQ
$13.31
$1.55B mkt cap·Price updated May 6, 2026
AboutIntellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA$0+100.0%
- Net Income-$413M+20.5%
- EPS (Diluted)-3.81+27.4%
- ROE-53.48%+1.0%
- Debt/Equity0.14-42.3%
NTLA Key Insights
Intellia Therapeutics, Inc. (NTLA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NTLA Price & Volume
Intellia Therapeutics, Inc. (NTLA) stock price & volume — 10-year historical chart
Loading chart...
NTLA Growth Metrics
Intellia Therapeutics, Inc. (NTLA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM20.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM27.43%
Return on Capital
10 Years-31.96%
5 Years-38.24%
3 Years-43.56%
Last Year-
NTLA Recent Earnings
Intellia Therapeutics, Inc. (NTLA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)
Q1 2026Latest
Feb 26, 2026EPS
$0.83
Est $0.99
+16.2%
Revenue
$23M
Est $12M
+92.1%
Q4 2025
Nov 6, 2025EPS
$0.92
Est $1.02
+9.8%
Revenue
$14M
Est $12M
+13.2%
Q3 2025
Aug 7, 2025EPS
$0.99
Est $1.03
+3.9%
Revenue
$14M
Est $14M
+1.3%
Q2 2025
May 8, 2025EPS
$1.10
Est $1.26
+12.7%
Revenue
$17M
Est $12M
+39.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.83vs $0.99+16.2% | $23Mvs $12M+92.1% |
| Q4 2025 | Nov 6, 2025 | $0.92vs $1.02+9.8% | $14Mvs $12M+13.2% |
| Q3 2025 | Aug 7, 2025 | $0.99vs $1.03+3.9% | $14Mvs $14M+1.3% |
| Q2 2025 | May 8, 2025 | $1.10vs $1.26+12.7% | $17Mvs $12M+39.3% |
Based on last 12 quarters of dataView full earnings history →
NTLA Peer Comparison
Intellia Therapeutics, Inc. (NTLA) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EDIT | 297.52M | 3.04 | -1.69 | -100% | -5.23% | 0.66 | ||
 CRSP | 4.92B | 52.38 | -8.10 | -89.97% | -13.29% | -25.49% | 0.11 | |
 BEAM | 2.97B | 28.90 | -35.68 | 120.01% | -57.24% | -7.31% | 0.24 | |
 SGMO | 37.8M | 0.18 | -0.36 | -67.2% | -331.28% | -8.14% | 1.34 | |
 RCKT | 383.45M | 3.54 | -1.76 | -80.49% | 0.09 | |||
 RARE | 2.46B | 25.01 | -4.29 | 20.13% | -85.54% | -9.11% | ||
 ARCT | 239.04M | 8.41 | -3.50 | -51.43% | -88.75% | -29.13% | 0.12 | |
 REGN | 72.97B | 702.33 | 16.93 | 0.99% | 29.65% | 14.32% | 5.59% | 0.09 |
Compare NTLA vs Peers
Intellia Therapeutics, Inc. (NTLA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NTLA Income Statement
Intellia Therapeutics, Inc. (NTLA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 26.12M | 30.43M | 43.1M | 57.99M | 33.05M | 52.12M | 36.27M | 57.88M | 0 |
| Revenue Growth % | 58.49% | 16.53% | 41.63% | 34.55% | -43.01% | 57.69% | -30.4% | 59.55% | -100% |
| Cost of Goods Sold | 67.65M | 89.11M | 108.41M | 150.41M | 6.89M | 7.57M | 8.98M | 10.29M | 0 |
| COGS % of Revenue | 259.02% | 292.81% | 251.52% | 259.35% | 20.85% | 14.53% | 24.74% | 17.77% | - |
| Gross Profit | -41.53M▲ 0% | -58.68M▼ 41.3% | -65.31M▼ 11.3% | -92.41M▼ 41.5% | 26.16M▲ 128.3% | 44.55M▲ 70.3% | 27.3M▼ 38.7% | 47.59M▲ 74.3% | 0▼ 100.0% |
| Gross Margin % | -159.02% | -192.81% | -151.52% | -159.35% | 79.15% | 85.47% | 75.26% | 82.23% | - |
| Gross Profit Growth % | -170.36% | -41.3% | -11.3% | -41.5% | 128.31% | 70.28% | -38.72% | 74.34% | -100% |
| Operating Expenses | 95.67M | 121.3M | 41.06M | 44.17M | 294.01M | 502.71M | 542.59M | 581.86M | 508.66M |
| OpEx % of Revenue | 366.32% | 398.58% | 95.26% | 76.16% | 889.52% | 964.51% | 1495.77% | 1005.33% | - |
| Selling, General & Admin | 28.02M | 32.19M | 41.06M | 44.17M | 71.1M | 90.31M | 116.5M | 125.83M | 119.8M |
| SG&A % of Revenue | 107.31% | 105.77% | 95.26% | 76.16% | 215.1% | 173.26% | 321.15% | 217.41% | - |
| Research & Development | 67.65M | 89.11M | 108.41M | 150.41M | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M |
| R&D % of Revenue | 259.02% | 292.81% | 251.52% | 259.35% | 695.27% | 805.78% | 1199.36% | 805.69% | - |
| Other Operating Expenses | 0 | 0 | -108.41M | -150.41M | -6.89M | -7.57M | -8.98M | -10.29M | 0 |
| Operating Income | -69.56M▲ 0% | -90.87M▼ 30.6% | -106.37M▼ 17.1% | -136.58M▼ 28.4% | -267.85M▼ 96.1% | -458.16M▼ 71.1% | -515.29M▼ 12.5% | -534.26M▼ 3.7% | 0▲ 100.0% |
| Operating Margin % | -266.32% | -298.58% | -246.78% | -235.51% | -810.37% | -879.04% | -1420.51% | -923.1% | - |
| Operating Income Growth % | -116.28% | -30.64% | -17.06% | -28.41% | -96.11% | -71.05% | -12.47% | -3.68% | 100% |
| EBITDA | -66.56M | -86.41M | -100.78M | -130.27M | -260.96M | -450.59M | -506.31M | -523.98M | 0 |
| EBITDA Margin % | -254.86% | -283.91% | -233.81% | -224.63% | -789.52% | -864.51% | -1395.77% | -905.33% | - |
| EBITDA Growth % | -114.33% | -29.81% | -16.64% | -29.26% | -100.32% | -72.67% | -12.37% | -3.49% | 100% |
| D&A (Non-Cash Add-back) | 2.99M | 4.46M | 5.59M | 6.31M | 6.89M | 7.57M | 8.98M | 10.29M | 0 |
| EBIT | -69.56M | -90.87M | -106.37M | -136.58M | -267.85M | -458.16M | -515.29M | -534.26M | 0 |
| Net Interest Income | 2.01M | 5.53M | 6.83M | 2.35M | 1.28M | 8.54M | 49.83M | 47.81M | 0 |
| Interest Income | 2.01M | 5.53M | 6.83M | 2.35M | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 2.01M | 5.53M | 6.83M | 2.35M | -42K | -16.02M | 34.1M | 15.24M | 0 |
| Pretax Income | -67.54M▲ 0% | -85.34M▼ 26.4% | -99.53M▼ 16.6% | -134.23M▼ 34.9% | -267.89M▼ 99.6% | -474.19M▼ 77.0% | -481.19M▼ 1.5% | -519.02M▼ 7.9% | -412.69M▲ 20.5% |
| Pretax Margin % | -258.62% | -280.42% | -230.92% | -231.46% | -810.49% | -909.78% | -1326.51% | -896.77% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -67.54M▲ 0% | -85.34M▼ 26.4% | -99.53M▼ 16.6% | -134.23M▼ 34.9% | -267.89M▼ 99.6% | -474.19M▼ 77.0% | -481.19M▼ 1.5% | -519.02M▼ 7.9% | -412.69M▲ 20.5% |
| Net Margin % | -258.62% | -280.42% | -230.92% | -231.46% | -810.49% | -909.78% | -1326.51% | -896.77% | - |
| Net Income Growth % | -113.51% | -26.35% | -16.63% | -34.86% | -99.58% | -77.01% | -1.48% | -7.86% | 20.49% |
| Net Income (Continuing) | -67.54M | -85.34M | -99.53M | -134.23M | -267.89M | -474.19M | -481.19M | -519.02M | -412.69M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.88▲ 0% | -1.98▼ 5.3% | -1.96▲ 1.0% | -2.40▼ 22.4% | -3.78▼ 57.5% | -6.16▼ 63.0% | -5.42▲ 12.0% | -5.25▲ 3.1% | -3.81▲ 27.4% |
| EPS Growth % | -106.59% | -5.32% | 1.01% | -22.45% | -57.5% | -62.96% | 12.01% | 3.14% | 27.43% |
| EPS (Basic) | -1.88 | -1.98 | -1.96 | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 |
| Diluted Shares Outstanding | 36.01M | 43.07M | 47.25M | 55.99M | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
| Basic Shares Outstanding | 36.01M | 43.07M | 47.25M | 55.99M | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
NTLA Balance Sheet
Intellia Therapeutics, Inc. (NTLA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 354.83M | 324.98M | 289.48M | 616.52M | 769.3M | 1.22B | 998.33M | 639.86M | 527.71M |
| Cash & Short-Term Investments | 340.68M | 314.06M | 279.73M | 597.37M | 748.69M | 1.19B | 912.22M | 601.51M | 449.88M |
| Cash Only | 340.68M | 58.86M | 57.23M | 160.02M | 123.41M | 523.51M | 226.75M | 189.18M | 155.46M |
| Short-Term Investments | 0 | 255.2M | 222.5M | 437.35M | 625.28M | 669.12M | 685.48M | 412.33M | 294.42M |
| Accounts Receivable | 10.47M | 7.55M | 4.62M | 2.13M | 2.03M | 3.77M | 36.46M | 8.52M | 9.47M |
| Days Sales Outstanding | 146.34 | 90.51 | 39.12 | 13.41 | 22.43 | 26.39 | 366.82 | 53.71 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 3.68M | 3.37M | 0 | 0 | 0 | 20.41M | 49.65M | 29.83M | 68.36M |
| Total Non-Current Assets | 21.41M | 22.34M | 44.8M | 59.8M | 525.16M | 303.32M | 302.65M | 551.15M | 314.42M |
| Property, Plant & Equipment | 15.27M | 17.06M | 37.13M | 55.06M | 100.11M | 161M | 148.13M | 246.67M | 123.63M |
| Fixed Asset Turnover | 1.71x | 1.78x | 1.16x | 1.05x | 0.33x | 0.32x | 0.24x | 0.23x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 4.75M | 4.75M | 425.05M | 142.32M | 154.51M | 44.26M | 35.54M |
| Other Non-Current Assets | 6.13M | 5.28M | 2.92M | 0 | 0 | 0 | 0 | 260.21M | 155.25M |
| Total Assets | 376.24M▲ 0% | 347.31M▼ 7.7% | 334.28M▼ 3.8% | 676.32M▲ 102.3% | 1.29B▲ 91.4% | 1.52B▲ 17.4% | 1.3B▼ 14.4% | 1.19B▼ 8.5% | 842.13M▼ 29.3% |
| Asset Turnover | 0.07x | 0.09x | 0.13x | 0.09x | 0.03x | 0.03x | 0.03x | 0.05x | - |
| Asset Growth % | 25.84% | -7.69% | -3.75% | 102.32% | 91.4% | 17.43% | -14.42% | -8.45% | -29.29% |
| Total Current Liabilities | 31.36M | 40.57M | 35.63M | 64.25M | 125.83M | 126.55M | 115.21M | 110.85M | 103.88M |
| Accounts Payable | 2.17M | 2.71M | 3.94M | 10.46M | 9.65M | 5.15M | 7.45M | 14.59M | 20.25M |
| Days Payables Outstanding | 11.72 | 11.09 | 13.27 | 25.38 | 511.3 | 248.44 | 303.03 | 517.74 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.48M |
| Deferred Revenue (Current) | 21.19M | 27.12M | 12.67M | 22.54M | 63.76M | 43.84M | 22.14M | 20.66M | 7.29M |
| Other Current Liabilities | 3.23M | 4.57M | 6.31M | 10.92M | 20.36M | 21.78M | 6.89M | 55.35M | 70.11M |
| Current Ratio | 11.32x | 8.01x | 8.12x | 9.59x | 6.11x | 9.61x | 8.67x | 5.77x | 5.08x |
| Quick Ratio | 11.32x | 8.01x | 8.12x | 9.59x | 6.11x | 9.61x | 8.67x | 5.77x | 5.08x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 44.28M | 28.82M | 28.77M | 85M | 128.39M | 157.98M | 135.6M | 208.21M | 66.85M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 66.85M |
| Capital Lease Obligations | 0 | 0 | 12.63M | 33.61M | 64.91M | 114.02M | 96.75M | 189.95M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | -38.85M | 0 | 0 |
| Other Non-Current Liabilities | 168K | 13K | 0 | 0 | 0 | 24.03M | 38.85M | 0 | 0 |
| Total Liabilities | 75.64M | 69.39M | 64.4M | 149.25M | 254.22M | 284.53M | 250.81M | 319.06M | 170.73M |
| Total Debt | 0 | 0 | 18.38M | 39.3M | 74.02M | 130.7M | 115.35M | 210.2M | 93.33M |
| Net Debt | -340.68M | -58.86M | -38.85M | -120.72M | -49.38M | -392.8M | -111.4M | 21.02M | -62.13M |
| Debt / Equity | - | - | 0.07x | 0.07x | 0.07x | 0.11x | 0.11x | 0.24x | 0.14x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | 300.6M▲ 0% | 277.92M▼ 7.5% | 269.88M▼ 2.9% | 527.07M▲ 95.3% | 1.04B▲ 97.4% | 1.24B▲ 18.8% | 1.05B▼ 15.0% | 871.96M▼ 17.0% | 671.39M▼ 23.0% |
| Equity Growth % | 43.25% | -7.54% | -2.89% | 95.3% | 97.36% | 18.78% | -15.01% | -16.97% | -23% |
| Book Value per Share | 8.35 | 6.45 | 5.71 | 9.41 | 14.67 | 16.05 | 11.83 | 8.82 | 6.20 |
| Total Shareholders' Equity | 300.6M | 277.92M | 269.88M | 527.07M | 1.04B | 1.24B | 1.05B | 871.96M | 671.39M |
| Common Stock | 4K | 5K | 5K | 7K | 7K | 9K | 9K | 10K | 12K |
| Retained Earnings | -121.11M | -201.03M | -300.88M | -435.11M | -703M | -1.18B | -1.66B | -2.18B | -2.59B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -28K | 261K | 1K | -2.63M | -7.46M | -2.26M | 605K | 1.03M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NTLA Cash Flow Statement
Intellia Therapeutics, Inc. (NTLA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -65.28M | -61.26M | -103.24M | -49.91M | -225.03M | -333.29M | -394.09M | -348.88M | -348.88M |
| Operating CF Margin % | -249.94% | -201.28% | -239.52% | -86.06% | -680.82% | -639.45% | -1086.38% | -602.8% | - |
| Operating CF Growth % | -280.77% | 6.16% | -68.54% | 51.65% | -350.85% | -48.11% | -18.24% | 11.47% | 0% |
| Net Income | -67.54M | -85.34M | -99.53M | -134.23M | -267.89M | -474.19M | -481.19M | -519.02M | -519.02M |
| Depreciation & Amortization | 2.99M | 4.46M | 5.59M | 6.31M | 6.89M | 7.57M | 8.98M | 10.29M | 10.29M |
| Stock-Based Compensation | 15.32M | 17.05M | 15.09M | 19.9M | 47.01M | 91.4M | 134.05M | 154.27M | 154.27M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 8.93M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 166K | -601K | -3.72M | 573K | 2.94M | 95.8M | -3.47M | -6.29M | 5.58M |
| Working Capital Changes | -16.21M | 3.18M | -20.66M | 57.53M | -22.9M | -53.87M | -52.45M | 11.88M | 0 |
| Change in Receivables | -4.02M | 2.92M | 2.93M | 2.49M | 99K | -1.74M | -32.69M | 27.94M | 27.94M |
| Change in Inventory | 1.28M | 3.96M | 1.65M | 0 | 7.82M | 0 | 0 | 0 | 0 |
| Change in Payables | -488K | 232K | 1.88M | 5.06M | 529K | -4.58M | 2.52M | 6.8M | 6.8M |
| Cash from Investing | -10.09M | -260.78M | 25.18M | -214.49M | -550.78M | 160.31M | -31.35M | 125.57M | 125.57M |
| Capital Expenditures | -10.09M | -6.36M | -6.79M | -3.58M | -12.76M | -58.39M | -13.98M | -5.78M | -5.78M |
| CapEx % of Revenue | 38.64% | 20.89% | 15.76% | 6.18% | 38.59% | 112.03% | 38.55% | 9.98% | - |
| Acquisitions | 0 | 131K | -31.97M | 0 | -3M | -44.68M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -10.1K | 131K | 31.97M | 0 | 0 | 44.83M | 0 | 0 | 20.97M |
| Cash from Financing | 142.98M | 40.22M | 76.43M | 371.78M | 736.69M | 582.96M | 130.32M | 185.75M | 185.75M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.98M | 11.67M | 4.18M | 13.13M | 43.12M | 17.17M | 10.53M | 8.85M | 185.75M |
| Net Change in Cash | 67.61M▲ 0% | -281.82M▼ 516.8% | -1.63M▲ 99.4% | 107.38M▲ 6687.7% | -39.12M▼ 136.4% | 409.98M▲ 1148.0% | -295.11M▼ 172.0% | -37.57M▲ 87.3% | -37.57M▲ 0.0% |
| Free Cash Flow | -75.37M▲ 0% | -67.61M▲ 10.3% | -110.03M▼ 62.7% | -53.5M▲ 51.4% | -237.79M▼ 344.5% | -391.68M▼ 64.7% | -408.07M▼ 4.2% | -354.66M▲ 13.1% | -354.66M▲ 0.0% |
| FCF Margin % | -288.57% | -222.17% | -255.28% | -92.25% | -719.41% | -751.48% | -1124.94% | -612.78% | - |
| FCF Growth % | -351.69% | 10.29% | -62.74% | 51.38% | -344.48% | -64.72% | -4.19% | 13.09% | 0% |
| FCF per Share | -2.09 | -1.57 | -2.33 | -0.96 | -3.35 | -5.09 | -4.60 | -3.59 | -3.27 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.72x | 1.04x | 0.37x | 0.84x | 0.70x | 0.82x | 0.67x | 0.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NTLA Key Ratios
Intellia Therapeutics, Inc. (NTLA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -22.82% | -26.46% | -29.5% | -36.34% | -33.69% | -34.18% | -41.67% | -42.1% | -54% | -53.48% |
| Return on Invested Capital (ROIC) | - | - | -76.16% | -35.45% | -32.14% | -28.76% | -37.48% | -43.39% | -43.75% | - |
| Gross Margin | -93.22% | -159.02% | -192.81% | -151.52% | -159.35% | 79.15% | 85.47% | 75.26% | 82.23% | - |
| Net Margin | -191.97% | -258.62% | -280.42% | -230.92% | -231.46% | -810.49% | -909.78% | -1326.51% | -896.77% | - |
| Debt / Equity | - | - | - | 0.07x | 0.07x | 0.07x | 0.11x | 0.11x | 0.24x | 0.14x |
| FCF Conversion | -1.14x | 0.97x | 0.72x | 1.04x | 0.37x | 0.84x | 0.70x | 0.82x | 0.67x | 0.85x |
| Revenue Growth | 172.65% | 58.49% | 16.53% | 41.63% | 34.55% | -43.01% | 57.69% | -30.4% | 59.55% | -100% |
NTLA SEC Filings & Documents
Intellia Therapeutics, Inc. (NTLA) SEC filings — annual & quarterly reports (10-K, 10-Q)
NTLA Frequently Asked Questions
Intellia Therapeutics, Inc. (NTLA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Intellia Therapeutics, Inc. (NTLA) saw revenue decline by 100.0% over the past year.
Intellia Therapeutics, Inc. (NTLA) reported a net loss of $412.7M for fiscal year 2025.
Dividend & Returns
Intellia Therapeutics, Inc. (NTLA) has a return on equity (ROE) of -53.5%. Negative ROE indicates the company is unprofitable.
Intellia Therapeutics, Inc. (NTLA) had negative free cash flow of $354.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More NTLA
Intellia Therapeutics, Inc. (NTLA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates